Abstract
Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucous membranes. Cold medicines including non-steroidal anti-inflammatory drugs and multi-ingredient cold medications are reported to be important inciting drugs. Recently, we reported that cold medicine related SJS/TEN (CM-SJS/TEN) with severe mucosal involvement including severe ocular surface complications (SOC) is associated with HLA-A*02:06 and HLA-B*44:03 in the Japanese. In this study, to determine whether HLA-B*44:03 is a common risk factor for CM-SJS/TEN with SOC in different ethnic groups we used samples from Indian, Brazilian, and Korean patients with CM-SJS/TEN with SOC, and investigated the association between CM-SJS/TEN with SOC and HLA-B*44:03 and/or HLA-A*02:06. We found that HLA-B*44:03 was significantly associated with CM-SJS/TEN with SOC in the Indian and Brazilian but not the Korean population, and that HLA-A*02:06 might be weakly associated in the Korean- but not the Indian and Brazilian population.
Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN) with spots, are acute inflammatory vesiculobullous reactions of the skin and mucous membranes such as the ocular surface, oral cavity, and genitals. They are rare but often associated with inciting drugs and/or infectious agents1,2,3.
The association between human leukocyte antigen (HLA) genotypes and drug-induced severe cutaneous adverse reactions (SCARs) including SJS/TEN has been reported. There was a strong association between HLA-B*58:01 and SCARs, including SJS/TEN and the drug-induced hypersensitivity syndrome (DIHS), induced by the uric acid lowering drug allopurinol. This association was observed in Han Chinese-4, Caucasian-5, and Japanese patients6, suggesting that different ethnic groups share the same risk factor(s) for allopurinol-induced SCARs. HLA-B*15:02 exhibited a very strong association with carbamazepine-induced SJS/TEN in Taiwanese Han Chinese patients7 and HLA-A*31:01 was strongly associated with carbamazepine-induced SCARs including SJS/TEN in Japanese-8 and European patients9. We recently reported that cold medicine-related SJS/TEN with severe mucosal involvement including severe ocular surface complications (SOC) is associated with HLA-A*02:06 and HLA-B*44:03 in Japanese patients10.
The ophthalmologists Mondino et al.11 and the dermatologists Roujeau et al.12,13 reported that HLA-B12 (HLA-Bw44) was significantly increased in Caucasian SJS patients many of whom developed SJS/TEN after taking non-steroidal anti-inflammatory drugs (NSAIDs). HLA-B12 is primarily coded by HLA-B*44:02 or HLA-B*44:03 (http://www.allelefrequencies.net/). The significant association between HLA-B12 and SJS/TEN in Caucasian patients may be attributable to their genetic background.
To determine whether HLA-B*44:03 is a common risk factor for CM-SJS/TEN with SOC in different ethnic groups we used samples from Indian, Brazilian, and Korean patients with CM-SJS/TEN with SOC, and investigated the association between CM-SJS/TEN with SOC and HLA-B*44:03 and/or HLA-A*02:06.
Methods
Our study was approved by the institutional review boards of the participating institutions. All experimental procedures were conducted in accordance with the principles of the Helsinki Declaration. The purpose of the research and the experimental protocols were explained to all participants, and their prior written informed consent was obtained.
Patients and controls
Ophthalmologists diagnosed SJS/TEN based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions, and involvement of at least two mucosal sites including the ocular surface1,14,15. They defined patients with SOC as those who manifested a pseudomembrane and an epithelial defect on the ocular surface in the acute stage, and as patients with ocular sequelae such as dry eye, trichiasis, symblepharon, and conjunctival invasion into the cornea in the chronic stage.
As in our previous study, we focused on SJS/TEN with SOC suspected of having been induced by cold medicines such as multi-ingredient cold medications and NSAIDs. As we found earlier that the genetic predisposition might be different between SJS/TEN with and without severe mucosal involvement including SOC10 we focused on patients from different ethnic groups who presented with SJS/TEN with SOC.
Samples from Indian patients with CM-SJS/TEN were collected at the LV Prasad Eye Institute (n = 20; 12 males, 8 females; age range 7 to 63 years; median age 27.1 ± 13.4 (SD) years). Their age at onset ranged from 3 to 42 years (median age at onset, 19.2 ± 12.2 (SD) years; in 8 patients the age at onset was unknown). The drugs administered to these patients and the HLA type (A and B) of patients with CM-SJS/TEN with SOC are shown in Supplemental Table 1. The specific drug(s) were not known in all patients. Healthy volunteers (n = 55; 29 males, 26 females; median age 36.0 ± 11.6 years) served as the Indian controls.
Samples from Brazilian patients with CM-SJS/TEN were collected at the Federal University of Sao Paulo (n = 39, 15 males, 24 females; age range 13 to 69 years; median age, 37.1 ± 15.9 years; age range at onset, 3 to 69 years; median age at onset, 24.0 ± 17.2 years). The drugs administered, the ethnicity, and the HLA type (A and B) of these CM-SJS/TEN patients with SOC are shown in Supplemental Table 2. Healthy volunteers (n = 134; 55 males, 79 females; median age 41.2 ± 12.8 years) were the Brazilian controls (ethnicity: pardo, n = 66; white, n = 62; black, n = 4, Indian plus white, n = 2).
Samples from Korean patients with CM-SJS/TEN were collected at the Seoul National University College of Medicine, Chonnam National University, Yonsei University, and the Catholic University of Korea. There were 31 patients (12 males, 19 females) ranging in age from 4 to 71 years (median age 33.7 ± 19.0 years). Their age at SJS/TEN onset ranged from 3 to 63 years (median age at onset, 23.0 ± 16.1 years). The drugs used and the HLA type (A and B) of these patients with SOC are presented in Supplemental Table 3. The specific drug(s) were not known in all patients. Healthy volunteers (n = 90; 35 males, 55 females; median age 31.7 ± 7.9 years) were the Korean controls.
Samples from Indian subjects were obtained by extracting DNA from whole peripheral blood with the phenol chloroform method. For Brazilian samples, DNA was extracted from whole peripheral blood using the PAX gene blood DNA kit (Qiagen, Hilden, Germany) or from saliva using Oragene DNA (Kyodou International, Kanagawa, Japan). To obtain the samples from Korean subjects, DNA was extracted from whole peripheral blood using the PAXgene Blood DNA kit (Qiagen).
HLA genotyping
For the analysis of HLA-A and HLA-B we performed polymerase chain reaction (PCR) assays followed by hybridization with sequence-specific oligonucleotide probes using commercial bead-based typing kits (Wakunaga, Hiroshima, Japan). Briefly, the target DNA was PCR-amplified with biotinylated primers specifically designed for amplified exons 2 and 3 of HLA-A, and -B genes. Then the PCR amplicon was denatured and hybridized to complementary oligonucleotide probes (72 probes for HLA-A, 93 probes for HLA-B) immobilized on fluorescent-coded microsphere beads. At the same time, the biotinylated PCR product was labeled with phycoerythrin-conjugated streptavidin and immediately examined with Luminex 100 (Luminex, Austin, TX, USA). Genotype determination and data analysis were performed automatically using the WAKFLOW typing software (Wakunaga, Hiroshima, Japan) according to the manufacturer's instructions.
Statistical analysis
We compared the carrier frequency and gene frequency of individual HLA alleles in the patients and controls with the χ2-test (Pearson) (JMP version 11 software; SAS Institute Japan Ltd., Tokyo, Japan).
Results
Strong association between HLA-B*44:03 and CM-SJS/TEN with SOC in Indian patients
We genotyped HLA-A and HLA-B in samples from Indian subjects (20 CM-SJS/TEN with SOC patients and 55 controls). Although the number of Indian subjects was small, we found a strong and significant association between their CM-SJS/TEN with SOC and HLA-B*44:03 (carrier frequency: p = 1.07 × 10−5, odds ratio (OR) = 12.25, gene frequency: p = 9.37 × 10−8, OR = 10.88) but not HLA-A*0206 (Table 1).
Table 1. Results of association analyses in patients with CM-SJS/TEN with SOC.
| Carrier frequency (%) | Dominant model analysis | Gene frequency (%) | Dominant model analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Odds ratio | Odds ratio | ||||||||||
| ethnic group | HLA genotype | CM-SJS/TEN with SOC | Control | P | Pc | (95% CI) | CM-SJS/TEN with SOC | Control | P | Pc | (95% CI) |
| Indian | A*02:06 | 1/20 (5.0%) | 3/55 (5.5%) | 0.938 | - | 0.91 (0.09–9.31) | 1/39 (2.5%) | 3/110 (2.7%) | 0.939 | - | 0.91 (0.09–9.06) |
| B*44:03 | 12/20 (60.0%) | 6/55 (10.9%) | 1.07.E-05 | 2.14.E-05 | 12.25 (3.57–42.01) | 17/40 (42.5%) | 7/110 (6.4%) | 9.37.E-08 | 1.87.E-07 | 10.88 (4.04–29.3) | |
| Brazilian | A*02:06 | 0/39 (0.00%) | 0/134 (0.00%) | - | - | - | 0/78 (0.00%) | 0/268 (0.00%) | - | - | - |
| B*44:03 | 10/39 (25.6%) | 15/134 (11.2%) | 0.0239 | 0.0478 | 2.74 (1.12–6.71) | 11/78 (14.1%) | 15/268 (5.60%) | 0.0121 | 0.0242 | 2.77 (1.22–6.31) | |
| Korean | A*02:06 | 11/31 (35.5%) | 14/90 (15.6%) | 0.0181 | 0.0362 | 3.00 (1.18–7.57) | 12/62 (19.4%) | 16/180 (8.9%) | 0.0263 | 0.0526 | 2.46 (1.09–5.54) |
| B*44:03 | 6/31 (19.4%) | 18/90 (20.0%) | 0.938 | - | 0.96 (0.34–2.69) | 7/62 (11.3%) | 19/180 (10.6%) | 0.872 | - | 1.07 (0.43–2.70) | |
P: P values obtained with the χ2-test (Pearson), CI: Confidence interval.
Pc: P values corrected for the multiplicity of testing by the number of comparisons 2 (HLA-A*02:06 + HLA-B*44:03).
CM-SJS/TEN: cold medicine-related SJS/TEN, SOC: severe ocular surface complications.
Significant association between HLA-B*44:03 and CM-SJS/TEN with SOC in Brazilian patients
Next we genotyped HLA-A and HLA-B in samples from Brazilian subjects (39 CM-SJS/TEN with SOC patients and 134 controls). Although the number of Brazilian subjects was small we found a significant association between Brazilian patients with CM-SJS/TEN with SOC and HLA-B*44:03 (carrier frequency: p = 0.0239, OR = 2.74, gene frequency: p = 0.0121, OR = 2.77) but not HLA-A*0206 which is absent in the Brazilian population (Table 1). Interestingly, in Caucasians in the Brazilian samples (Brazilian Caucasian CM-SJS/TEN with SOC patients: n = 15, Brazilian Caucasian controls: n = 62), the association with HLA-B*44:03 was stronger (carrier frequency: p = 0.0037, OR = 6.22, gene frequency: p = 0.0011, OR = 5.99).
Association between HLA-A*02:06 and Korean patients with CM-SJS/TEN with SOC
We also genotyped HLA-A and HLA-B in samples from Koreans (31 patients with CM-SJS/TEN with SOC and 90 controls). Although the number of Korean patients was small we found a significant association between patients with CM-SJS/TEN with SOC and HLA-A*0206 (carrier frequency: p = 0.0362, OR = 3.00, gene frequency: p = 0.0263, OR = 2.46) but not HLA-B*44:03 (Table 1).
Discussion
We previously reported that in the Japanese, CM-SJS/TEN with severe mucosal involvement including SOC was associated with HLA-A*02:06 and HLA-B*44:0310. In the present study we investigated whether the association with these alleles is shared by other ethnic groups. We found that HLA-B*44:03 was strongly associated with CM-SJS/TEN with SOC in the Indian population which is genetically close to European populations16 and significantly associated in the Brazilian population which is comprised of individuals with different ethnic backgrounds. There was no association between HLA-B*44:03 and CM-SJS/TEN with SOC in the Korean population. HLA-A*02:06 was weakly associated in the Korean population which is genetically close to the Japanese, but not in the Indian and Brazilian population.
HLA-B12 (HLA-Bw44) was significantly increased in Caucasian SJS patients many of whom developed SJS/TEN after taking NSAIDs11,12,13. Because HLA-B12 is primarily coded by HLA-B*44:02 or HLA-B*44:03 (http://www.allelefrequencies.net/), the significant association of HLA-B12 with SJS/TEN in Caucasian patients may be attributable to the association with the HLA-B*44:03 genotype.
We also found that in Brazilian Caucasian patients with CM-SJS/TEN with SOC, the significant association with HLA-B*44:03 was stronger than in the entire study population of Brazilians with CM-SJS/TEN with SOC. To determine whether HLA-B*44:03 is a common marker for CM-SJS/TEN with SOC in Caucasian, HLA analysis of European patients with CM-SJS/TEN with SOC is needed.
Although HLA-A*02:06 was strongly associated with the Japanese CM-SJS/TEN with SOC, and the Korean and Japanese population is genetically close16, in Korean patients CM-SJS/TEN with SOC was not strongly associated with HLA-A*02:06. To determine whether HLA-A*02:06 is a common marker for CM-SJS/TEN with SOC in East Asian populations further investigations using a larger number of samples are needed.
We also performed a meta-analysis by adding our previously-reported samples10. We used Cochran-Mantel-Haenszel statistics and found that both HLA-A*02:06 and HLA-B*44:03 are significantly associated with CM-SJS/TEN with SOC (Supplemental Table 4).
SCARs including SJS/TEN and DIHS induced by allopurinol were commonly and strongly associated with HLA-B* 58:01 in patients of different ethnic backgrounds including Han Chinese-4, Caucasian-5, and Japanese patients6. This observation suggests that different ethnic groups share the same risk factor(s) for allopurinol-induced SCARs.
With respect to carbamazepine-induced SJS/TEN, different HLA alleles are associated. HLA-B*15:02 is associated in Taiwanese Han Chinese patients7 and HLA-A*31:01 in Japanese-8 and European patients9.
In CM-SJS/TEN with SOC, the associated alleles we identified are HLA-A*02:06 in Japanese and Korean patients and HLA-B*44:03 in Indian-, Brazilian-, and Japanese patients. Studies are underway to determine whether other HLA alleles are associated with CM-SJS/TEN with SOC in other populations.
Author Contributions
M.U. wrote the main manuscript text and prepared the tables. M.U., C.K., T.W., M.K., K.Y., K.S., C.J., V.S., V.R., S.B., A.S., H.L., S.Y., C.S., J.G., K.T. and S.K. contributed to material of the research and reviewed the manuscript.
Supplementary Material
Supplemental Tables
Acknowledgments
This work was conducted as part of the BioBank Japan Project supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government, and as part of the Promotion Project of Knowledge-Based Industrial Clustering of Okinawa Prefecture. It was supported in part by grants-in-aid for scientific research from the Japanese Ministry of Health, Labour and Welfare, a research grant from the Kyoto Foundation for the Promotion of Medical Science, and the Intramural Research Fund of Kyoto Prefectural University of Medicine. The funding agencies had no role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.
References
- Ueta M. et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 91, 962–965 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yamane Y., Aihara M. & Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 56, 419–425 (2007). [DOI] [PubMed] [Google Scholar]
- Yetiv J. Z., Bianchine J. R. & Owen J. A. Jr. Etiologic factors of the Stevens-Johnson syndrome. South Med J 73, 599–602 (1980). [DOI] [PubMed] [Google Scholar]
- Hung S. I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102, 4134–4139 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lonjou C. et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18, 99–107 (2008). [DOI] [PubMed] [Google Scholar]
- Tohkin M. et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 13, 60–69 (2013). [DOI] [PubMed] [Google Scholar]
- Chung W. H. et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004). [DOI] [PubMed] [Google Scholar]
- Ozeki T. et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Molec Genetics 20, 1034–1041 (2011). [DOI] [PubMed] [Google Scholar]
- McCormack M. et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364, 1134–1143 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ueta M. et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep 4, 4862 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mondino B. J., Brown S. I. & Biglan A. W. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol 100, 1453–1454 (1982). [DOI] [PubMed] [Google Scholar]
- Roujeau J. C. et al. HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 28, 251–254 (1986). [DOI] [PubMed] [Google Scholar]
- Roujeau J. C. et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123, 1171–1173 (1987). [PubMed] [Google Scholar]
- Ueta M. et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol 126, 1218–1225 e1210 (2010). [DOI] [PubMed] [Google Scholar]
- Ueta M., Sotozono C., Tokunaga K., Yabe T. & Kinoshita S. Strong association between HLA-A*0206 and Stevens-Johnson Syndrome in the Japanese. Am J Ophthalmol 143, 367–368 (2007). [DOI] [PubMed] [Google Scholar]
- Abdulla M. A. et al. Mapping human genetic diversity in Asia. Science 326, 1541–1545 (2009). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplemental Tables